Home topics news Credit: Brandon Capital News News Brandon Capital champions Aussie medical research with A$270 million fund Yajush Gupta June 5, 2024 At the 2024 BIO International Convention, Brandon Capital, a leading life sciences venture capital firm in Australasia, revealed the initial success of their sixth fund. Dr. Chris Nave, co-founder and managing partner, announced a A$270 million first close for the fund and ongoing discussions with additional investors. Fund VI will allow Brandon Capital to continue seeding new life sciences startups in Australia and New Zealand while propelling their international expansion, particularly in the UK, Europe, and the US. Since its founding in 2007, Brandon Capital has secured over A$1 billion across five funds, supporting more than 60 new ventures in therapeutics, medical devices, and healthtech. As a prominent local life sciences specialist, Brandon Capital provides Australian superannuation funds a chance to diversify their portfolios and gain exposure to a sector with the potential for strong returns, social impact, and improved patient well-being. ”We deeply appreciate our LPs’ continued trust in Brandon Capital and their ongoing recognition that the Life Sciences sector is an exciting and rewarding venture capital asset class. As stewards of this capital, it is a privilege to invest in companies with the capacity to deliver both financial and health returns,” said Dr Chris Nave, Managing Partner of Brandon Capital. Highlighting Australia’s strength in medical research, Dr. Nave emphasized Brandon Capital’s role in supporting the translation of scientific discoveries into companies developing new treatments, vaccines,